Levosert

Levonorgestrel, the active ingredient in Levosert, is a progestin presented as a 20 µg/day release intrauterine system for intrauterine use. It prevents pregnancy in women of reproductive age by providing continuous hormonal contraception.

GNH USA supplies Levosert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levosert, a levonorgestrel‑releasing intrauterine system, provides long‑acting reversible contraception.

- Prevention of pregnancy: delivers a steady hormone dose to inhibit ovulation and prevent fertilisation for up to five years. - Long‑acting reversible contraception: offers a convenient, hormone‑based method without daily dosing. - Management of menstrual symptoms: can reduce heavy bleeding and dysmenorrhoea in users seeking hormonal regulation.

Levosert may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Irregular vaginal bleeding: spotting or breakthrough bleeding, especially during the first months. - Amenorrhoea: absence of menstrual periods after initial adjustment. - Pelvic or abdominal pain: cramping associated with insertion or hormonal effects. - Headache: mild to moderate intensity. - Breast tenderness: hormonal‑related discomfort. - Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects: - Uterine perforation: risk during insertion, requiring medical intervention. - Expulsion of the device: partial or complete loss of the IUS. - Pelvic infection: possible post‑insertion infection requiring antibiotics. - Ectopic pregnancy: rare but serious if pregnancy occurs. - Allergic reaction: rash, itching, or swelling at the insertion site. - Hormone‑related thromboembolic events: extremely rare clotting disorders.

Before using Levosert, certain precautions should be observed to ensure safety and effectiveness.

- Screen for pregnancy: confirm the patient is not pregnant prior to insertion. - Assess uterine anatomy: ensure the uterus is suitable for an intrauterine system. - Check contraindications: avoid use in active pelvic infection, known or suspected malignancy, or unexplained vaginal bleeding. - Monitor for device displacement: schedule follow‑up visits to verify correct positioning. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Levosert may interact with other medications that affect hormone metabolism or efficacy.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce levonorgestrel levels. - Rifampicin: can decrease hormonal effectiveness. - Certain antiretrovirals (e.g., efavirenz): may lower contraceptive efficacy.

Moderate Interactions (Monitor Closely): - Broad‑spectrum antibiotics (e.g., tetracycline): possible slight reduction in hormone levels. - Herbal supplements such as St. John’s wort: may affect levonorgestrel metabolism.